Holen Sie sich die Stockscreener-App
25.50
2.75%
-0.72
Handel nachbörslich:
25.50
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? - Yahoo Finance
Acadia rises as EU backs Rett syndrome therapy - MSN
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value? - Yahoo Finance
Why Acadia Pharmaceuticals stock is soaring today - MSN
ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win? - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change? - simplywall.st
How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors - Yahoo Finance
H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Carl Segerstrom Appointed Chief People Officer at Acadia Pharmaceuticals - hrtoday.in
Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative? - Sahm
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating - Moomoo
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer - BioSpace
ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News & Headlines - Yahoo Finance
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief Talent Officer - GuruFocus
Acadia taps 25-year HR veteran for chief people officer role - Stock Titan
ACADAcadia Pharmaceuticals Inc Forecast, Target Price - Finviz
Understanding the Setup: (ACAD) and Scalable Risk - Stock Traders Daily
Price to sales forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD - TradingView
Price to book forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD - TradingView
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
Price to earnings forward of ACADIA Pharmaceuticals Inc. – BIVA:ACAD - TradingView
Price to book forward of ACADIA Pharmaceuticals Inc. – LSX:603035 - TradingView
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results - Investing.com
ACAD stock eyes best day in over a year as CHMP recommends approval for rare nerve disorder drug in Europe - MSN
ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now - TMX Newsfile
ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds - simplywall.st
ACAD Maintains Buy Rating -- Price Target Raised to $30.00 by B of A Securities - GuruFocus
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $30 to $37 - Moomoo
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress - Investing.com Australia
ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup - Moomoo
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia Pharmaceuticals principal accounting officer sells $297,912 - Investing.com UK
Acadia Pharmaceuticals principal accounting officer sells $297,912 By Investing.com - Investing.com Nigeria
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Nigeria
ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan - Stock Titan
ACAD stock up as CHMP backs Daybu for EU approval in Rett syndrome - MSN
ACAD Maintained by Canaccord Genuity -- Price Target Raised to $36.00 - GuruFocus
ACAD Maintained by Citigroup -- Price Target Raised to $35 - GuruFocus
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome - The Globe and Mail
EMA reverses its stance on Acadia’s Rett syndrome therapy Daybu - BioWorld News
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus - Seeking Alpha
Acadia Pharmaceuticals (ACAD) Receives Positive CHMP Opinion for DAYBU Approval - GuruFocus
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus (NASDAQ:ACAD) - Seeking Alpha
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating - marketscreener.com
Canaccord raises Acadia Pharmaceuticals price target on EU approval By Investing.com - Investing.com Canada
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - BioSpace
Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $35 - Moomoo
5.60%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):